Over the last decades, several targeted agents as isocitrate dehydrogenase (IDH) inhibitors, fms-like tyrosine kinase 3 (FLT3) inhibitors, B-cell lymphoma 2 (BCL2) inhibitors, hypomethylating agents and menin inhibitors were developed and some were approved for AML therapy [5, 9–17]. Here, IDH2 is linked to acute myeloid leukemia.